Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

Phase III Study Assessing the Efficacy, Safety and Immunogenicity of SOK583A1 Versus Eylea® in Patients With Neovascular Age-related Macular Degeneration

ClinicalTrials.gov ID: NCT04864834

Public ClinicalTrials.gov record NCT04864834. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 8, 2026, 5:09 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A 52-week Multicenter, Randomized, Double-masked, 2-arm Parallel Study to Compare Efficacy, Safety and Immunogenicity of SOK583A1 to Eylea®, Administered Intravitreally, in Patients With Neovascular Age-related Macular Degeneration

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

Purpose and rationale: To demonstrate similar efficacy, safety and immunogenicity of SOK583A1 and Eylea EU as per Eylea approved treatment regimen in patients with nAMD. The primary clinical question of interest is: Does SOK583A1 have similar efficacy as Eylea EU in terms of mean change in BCVA score in participants with nAMD who are anti-VEGF naive, without important protocol deviations and adherent to the treatment and completed the treatment to Week 8?

Study identification

NCT ID
NCT04864834
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Sandoz
Industry
Enrollment
485 participants

Conditions and interventions

Eligibility (public fields only)

Age range
50 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
May 11, 2021
Primary completion
Jul 6, 2022
Completion
May 9, 2023
Last update posted
Mar 25, 2024

2021 – 2023

United States locations

U.S. sites
28
U.S. states
12
U.S. cities
28
Facility City State ZIP Site status
Sandoz Investigational Site Phoenix Arizona 85021
Sandoz Investigational Site Arcadia California 91006
Sandoz Investigational Site Campbell California 95008
Sandoz Investigational Site Encino California 91436
Sandoz Investigational Site Fullerton California 92835
Sandoz Investigational Site Glendale California 91203
Sandoz Investigational Site Huntington Beach California 92647
Sandoz Investigational Site Pasadena California 91107
Sandoz Investigational Site Poway California 92064
Sandoz Investigational Site Redlands California 92374
Sandoz Investigational Site Sacramento California 95841
Sandoz Investigational Site Fort Myers Florida 33912-7125
Sandoz Investigational Site Pinellas Park Florida 33782
Sandoz Investigational Site Plantation Florida 33324
Sandoz Investigational Site Stuart Florida 34994
Sandoz Investigational Site Marietta Georgia 30060
Sandoz Investigational Site Oak Forest Illinois 60452
Sandoz Investigational Site Hagerstown Maryland 21740
Sandoz Investigational Site Albuquerque New Mexico 87102
Sandoz Investigational Site Great Neck New York 11021
Sandoz Investigational Site Liverpool New York 13088
Sandoz Investigational Site Rochester New York 14620
Sandoz Investigational Site Eugene Oregon 97401
Sandoz Investigational Site Rapid City South Dakota 57701
Sandoz Investigational Site Abilene Texas 79606
Sandoz Investigational Site Arlington Texas 76012
Sandoz Investigational Site Willow Park Texas 76087
Sandoz Investigational Site Lynchburg Virginia 24502

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 74 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT04864834, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Mar 25, 2024 · Synced Sep 8, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT04864834 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →